Anti-Amphiregulin/AREG monoclonal antibody
The Alternative Names of target: Amphiregulin, AREG,Amphiregulin,AR,Colorectum cell-derived growth factor (CRDGF),AR,SDGF,AREGB,CRDGF
Pre-made anti-Amphiregulin/AREG monoclonal antibody (mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research.
Go
to Amphiregulin/AREG products collection
>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T92834-Ab-1/ GM-Tg-hg-T92834-Ab-2 | Anti-Human Amphiregulin/AREG monoclonal antibody | Human |
GM-Tg-rg-T92834-Ab-1/ GM-Tg-rg-T92834-Ab-2 | Anti-Rat Amphiregulin/AREG monoclonal antibody | Rat |
GM-Tg-mg-T92834-Ab-1/ GM-Tg-mg-T92834-Ab-2 | Anti-Mouse Amphiregulin/AREG monoclonal antibody | Mouse |
GM-Tg-cynog-T92834-Ab-1/ GM-Tg-cynog-T92834-Ab-2 | Anti-Cynomolgus/Rhesus macaque Amphiregulin/AREG monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T92834-Ab-1/ GM-Tg-felg-T92834-Ab-2 | Anti-Feline Amphiregulin/AREG monoclonal antibody | Feline |
GM-Tg-cang-T92834-Ab-1/ GM-Tg-cang-T92834-Ab-2 | Anti-Canine Amphiregulin/AREG monoclonal antibody | Canine |
GM-Tg-bovg-T92834-Ab-1/ GM-Tg-bovg-T92834-Ab-2 | Anti-Bovine Amphiregulin/AREG monoclonal antibody | Bovine |
GM-Tg-equg-T92834-Ab-1/ GM-Tg-equg-T92834-Ab-2 | Anti-Equine Amphiregulin/AREG monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. |
GM-Tg-hg-T92834-Ab-1/ GM-Tg-hg-T92834-Ab-2;
GM-Tg-rg-T92834-Ab-1/ GM-Tg-rg-T92834-Ab-2;
GM-Tg-mg-T92834-Ab-1/ GM-Tg-mg-T92834-Ab-2; GM-Tg-cynog-T92834-Ab-1/ GM-Tg-cynog-T92834-Ab-2; GM-Tg-felg-T92834-Ab-1/ GM-Tg-felg-T92834-Ab-2; GM-Tg-cang-T92834-Ab-1/ GM-Tg-cang-T92834-Ab-2; GM-Tg-bovg-T92834-Ab-1/ GM-Tg-bovg-T92834-Ab-2; GM-Tg-equg-T92834-Ab-1/ GM-Tg-equg-T92834-Ab-2 |
Products Name | Anti-Amphiregulin/AREG monoclonal antibody |
Format | mab |
Target Name | Amphiregulin/AREG |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category of antibody | Therapeutics Target, Cytokine Target |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) |
IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
Tag | Fc |
Products description | Pre-made anti-Amphiregulin/AREG monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution |
Lyophilized from GM's Protein Stability Buffer2
(PSB2,Confidential Ingredients) or PBS
(pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data/case study
Click to get more Data/Case study about the product.
About Gmab
GMab, developed by GeneMedi, constitutes an
advanced library of recombinant
monoclonal antibodies, each meticulously
designed to target specific molecular
entities. Leveraging the sophisticated
capabilities of GM’s Taurus™ and LIBRA™
platforms, GMab synthesizes antibodies
characterized by high binding affinity,
exceptional physicochemical stability, and
optimal developability profiles.
Through
expression in mammalian cell lines, GMab has
been established as a paradigmatic
reference antibody. It holds significance in
myriad domains of biological drug
discovery, encompassing cellular cultivation,
innovative assay methodologies,
strategic animal model systematization, in-depth
pharmacokinetic & pharmacodynamic
(PK/PD) modeling, and intricate mechanism of
action (MOA) investigations.
Comments
No comments yet.